Why the stock of Alkem Labs is a good ‘Buy’
The stock is suitable for long-term investors, given multiple positives and reasonable valuation
Alkem Laboratories, the fifth largest pharma company in India, is a dominant player in acute therapy areas with well-established brands.
The company is ranked number one market share in terms of revenue in anti-infectives. It also has the third largest market share each in gastro-intestinal and pain and analgesics therapies. Over the years, Alkem Labs has held on to or improved its rankings in these areas.
In the chronic segment too, which covers neurology, dermatology, cardiology and anti-diabetics, Alkem Labs, despite smaller presence, has managed to up its market share.
BENGALURU: A new study from IISc’s Centre for Neuroscience (CNS) has explored how well deep neural networks machine learning systems inspired by the network of brain cells or neurons in the human brain compare to the human brain when it comes to visual perception.
Pointing out that deep neural networks can be trained to perform specific tasks, researchers say that they have played a pivotal role in helping scientists understand how our brains perceive the things that we see.
“Although deep networks have evolved significantly over the past decade, they are still nowhere close to performing as well as the human brain in perceiving visual cues. In a recent study, SP Arun, associate professor at CNS, and his team have compared various qualitative properties of these deep networks with those of the human brain,” IISc said in a statement.